# From the INTERNATIONAL SEARCHING AUTHORITY

WILLIAM J. HONE

45 ROCKEFELLER PLAZA	OFFICE. C.		
SUITE 2800	NOTIFICATION OF TRANSMITTAL OF		
NEW YORK, NY 10111	THE INTERNATIONAL SEARCH REPORT		
	OR THE DECLARATION		
	OR THE BECEARATION		
	(PCT Rule 44.1)		
	`		
,	Date of Mailing		
	(day/month/year) 22 SEP 2000.		
Applicant's or agent's file reference			
07763/042WO1	FOR FURTHER ACTION See paragraphs 1 and 4 below		
International application No.	International filing date		
	(day/month/year)		
PCT/US00/12197 ·	04 MAY 2000		
Applicant			
THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE	CITY OF NEW YORK, INC.		
•			
1. X The applicant is hereby notified that the international	search report has been established and is transmitted herewith.		
Filing of amendments and statement under Article	e 19:		
The applicant is entitled, if he so wishes, to amend t	he claims of the international application (see Rule 46):		
When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.			
Where? Directly to the International Bureau of W	ЛРО		
34, chemin des Colombet	tes Search Report - RSpn		
1211 Geneva 20, Switzer Facsimile No.: (41-22) 7	40.14.35,7		
34, chemin des Colombettes  1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35  For more detailed instructions, see the notes on the accompanying sheet and the second			
For more detailed instructions, see the notes on the accompanying short and			
2. The applicant is hereby notified that no international search report will be established and that the declaration under			
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.			
3. With regard to the protest against payment of (an)	additional fee(s) under Rule 40.2, the applicant is notified that:		
the protect together with the decision thereon h	has been transmitted to the International Bureau together with the		
applicant's request to forward the texts of bot	h the protest and the decision thereon to the designated Offices.		
no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.			
	The state of the s		
4. Further action(s): The applicant is reminded of the following	llowing:		
Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.			
Within 19 months from the priority date, a demand for in	aternational preliminary examination must be filed if the applicant util 30 months from the priority date (in some Offices even later).		
Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.			
Name and mailing address of the ISA/US	Authorized officer Joseph Charles		
Commissioner of Patents and Trademarks			
Box PCT	RODNEY P. SWARTZ, PH.D.		

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Telephone No. (703)308-0196



# **PCT**

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 07763/042WO1	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.					
International application No.	International filing dat	(day/month/year) (Earliest) Priority Date (day/month/year)					
PCT/US00/12197	04 MAY 2000		04 MAY 1999				
Applicant THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC.							
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.							
This international search report consists	s of a total of ${\cal F}$ sheet	s.					
X It is also accompanied by a copy of each prior art document cited in this report.							
1. Basis of the report							
			sis of the international application in the				
language in which it was filed, unless otherwise indicated under this item.  the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).							
b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search							
was carried out on the basis of the sequence listing:  contained in the international application in written form.							
filed together with the interr							
furnished subsequently to th		_					
furnished subsequently to th	·						
	-		not go beyond the disclosure in the				
the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.							
furnished.	the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.						
	ns were found unsearchable (See Box I).						
3. X Unity of invention is lacking	Unity of invention is lacking (See Box II).						
4. With regard to the title,							
X the text is approved as subn	the text is approved as submitted by the applicant.						
the text has been established	by this Authority to rea	d as follows:					
•			,				
5. With regard to the abstract,							
X the text is approved as subn	nitted by the applicant.						
the text has been established Box III. The applicant may, search report, submit comm	within one month from th						
6. The figure of the drawings to be p	ublished with the abstract	t is Figure No					
as suggested by the applicar	nt.		X None of the figures.				
because the applicant failed	to suggest a figure.		None of the figures.				
because this figure better ch	-						



International application No. PCT/US00/12197

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:				
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
Please See Extra Sheet.				
·				
*				
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-20				
Remark on Protest The additional search fees were accompanied by the applicant's protest.				
No protest accompanied the payment of additional search fees.				

# INTERNATIONAL SEARCH REPORT

International application No.

	PCT/US	600/12197		
A. CLASSIFICATION OF SUBJECT MATTER				
IPC(7) :Please See Extra Sheet.				
US CL: Please See Extra Sheet.  According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system follower	d by classification symbols)			
U.S. : 424/185.1, 234.1, 248.1; 435/69.1, 71.1, 91.1, 253	.1; 530/300, 350; 536/22.1, 2	3.1, 23.7		
Documentation searched other than minimum documentation to the	extent that such documents are in	ncluded in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) FIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category* Citation of document, with indication, where ap	ges Relevant to claim No.			
MANCA, C. et al. MTC28, a novel 28-kilodalton proline-rich secreted antigen specific for the Mycobacterium tuberculosis complex. Infection and Immunity. December 1997, Vol. 65, No. 12, pages 4951-4957, entire reference.		losis		
characterization of MPT63, a new Mycobacterium tuberculosis. Infection	MANCA, C. et al. Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis. Infection and Immunity. January 1997, Vol. 65, No. 1, pages 16-23, entire reference.			
		Ÿ		
X Further documents are listed in the continuation of Box C	. See patent family as	nnex.		
*A* Special categories of cited documents:  "A* document defining the general state of the art which is not considered to be of particular relevance  "A* document defining the general state of the art which is not considered to be of particular relevance  "A* document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention				
"E" document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other				
special reason (as specified)  O document referring to an oral disclosure, use, exhibition or other means	considered to involve an	vance; the claimed invention cannot be inventive step when the document is other such documents, such combination killed in the art		
*P* document published prior to the international filing date but later than the priority date claimed	*&" document member of the sa	me patent family		
Date of the actual completion of the international search 06 SEPTEMBER 2000	Date of mailing of the internati	22 SEP 2000		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Footing No. (703) 305 3230	Authorized officer  RODNEY P. SWARTZ, P. Telephone No. (703) 708, 01	h		



	C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
Y	GENNARO, M.L. et al. Gene cloning and purification of proteins secreted by Mycobacterium tuberculosis. Journal of Cellular Biochemistry Supplement. 1995, Abstract No. B3-112, page 68, entire abstract.	1-20			
Y	ANDERSEN, P. et al. Proteins released from Mycobacterium tuberculosis during growth. Infection and Immunity. June 1991, Vol. 59, No. 6, pages 1905-1910, entire reference.	1-20			
Y	BORREMANS, M., et al. Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis. Infection and Immunity. October 1989, Vol. 57, No. 10, pages 3123-3130, entire reference.	1-20			
<b>Y</b>	CONTENT, J. et al. The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobacterium bovis BCG are members of a gene family: Cloning, sequence determination, and genomic organization of the gene coding for antigen 85-c of Mycobacterium tuberculosis. Infection and Immunity. September 1991, Vol. 59, No. 9, pages 3205-3212, entire reference.	1-20			
Y	HORWITZ, M.A. et al. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences, USA. February 1995, Vol. 92, pages 1530-1534, entire reference.	1-20			
Y	ROBERTS, A.D. et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology. 1995, Vol. 85, pages 502-508, entire reference.	1-20			
Y	MATSUMOTO, S. et al. Cloning and sequencing of a unique antigen MPT70 from Mycobacterium tuberculosis H37Rv and expression in BCG using E. coli-Mycobacteria shuttle vector. Scandinavian Journal of Immunology. 1995, Vol. 41, pages 281-287, entire reference.	1-20			
Y	LAQUEYRERIE, A. et al. Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45/47-kilodalton secreted antigen complex. Infection and Immunity. October 1995, Vol. 63, No. 10, pages 4003-4010, entire reference.	1-20			





International application No. PCT/US00/12197

A. CLASSIFICATION OF SUBJECT MATTER: IPC (7):

A61K 38/00, 39/00, 39/02, 39/04; C07H 21/02, 21/04; C07K 1/00, 14/00; C12N 1/12, 1/20; C12P 19/34, 21/04, 21/06

A. CLASSIFICATION OF SUBJECT MATTER:

US CL:

424/185.1, 234.1, 248.1; 435/69.1, 71.1, 91.1, 253.1; 530/300, 350; 536/22.1, 23.1, 23.7

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-20, drawn to DNA, vector, transformed cells, polypeptides, and a first method of use for diagnosis in vivo.

Group II, claims 21-24, drawn to second method of use for diagnosis in vitro using cells.

Group III, claims 25-28, drawn to third method of use for diagnosis in vitro using antibodies.

Group IV, claims 29-36, drawn to fourth method of use for vaccination.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the DNA is a single inventive concept, and as such the corresponding vectors, transformed cells, polypeptides encoded by the DNA, and a first method of use of the polypeptides are included in the first invention. The remaining Groups II-IV are additional methods of use, not requiring the DNA, but can utilize isolated and purified polypeptides obtained from M. tuberculosis.

#### NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

化工作机能 医海绵囊炎

e e la granda de la granda de la composição de la composi

The applicant has, other having received the international search report, one apportunity to amond the claims of the international application. It should however be complessed that, since all parts of the international application (claims, description and derivings) may be amonded during the international polintarry examination personals, there is usually no need to file amondments of the claims under Article 19 except where, e.g. the applicant would the inter to be published for the purposes of psychologic protection or has exother reason for amonding the claims before international publication. Purchasence, it should be complessized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

The claims only.

The description and the deswings may only be amended during international preliminary examination under Chapter IL

When? Within 2 meeths from the date of transmitted of the interactional search report or 16 meeths from the priority date, whichever these limit expires late. It should be noted, herevery, that the assendments will be considered as having been received on time if they are received by the interactional Burner other the expiration of the applicable time limit but before the completion of the technical preparations for interactional publication (Ride 46.1).

## Where not to the the emendments?

The emendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 44.2).

Where a demand for international peclimic ry examination has been a filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement short must be submitted for each short of the claims which, on account of an amendment or amendments, differs from the short originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be sommbered consecutively (Administrative Instructions, Section 205(b)).

#### What decuments must/may accompany the amendments?

Letter (Section 205(b)):

The emendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confounded with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged:
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

# NOTES TO FORM PCT/ISA/220 (continued)

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally these were 48 claims and after amendment of some claims there are \$1]:
  "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bessing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to \$1 added."
- 2. [Where originally there were 15 claims and after amendment of all claims there are 11]: Claims 1 to 15 seplected by amended claims 1 to 11."
- (Where originally there were 14 claims and the smeadments consist in cancelling some cl. icas and in adding new claims):
   "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added," or
   "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where verious kinds of amendments are made]:
  "Claims 1-10 unchanged; claims 11 to 13, 15 and 19 cancelled; claims 14, 15 and 16 replaced by amendoc claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

# "Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the deswings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

The statement should be brief, it should not exceed 500 words if in English or if itemsleted into English.

It should not be confounded with end does not replace the latter indicating the differences between the claims at Clod and an amended. It must be Clod on a appearing short and must be identified as such by a heading, perfectly by using the worls "Sustament under Article 19(1)."

It should not contain any dispensing comments on the international search report or the selevance of citations contained in that aspect. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

## In what language?

The amendments must be made in the language in which the international application is published. The letter and any statement accompanying the amendments must be in the same language as the international application if that language is English or French; otherwise, it must be in English or French, at the choice of the applicant.

# Consequence if a domand for international preliminary examination has already been filed?

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the international Preliminary Examining Authority (see Rule 62.2(a), first sentence).

# Consequence with regard to translation of the international application for entry into the national phase?

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.